York Space Systems And 2 US Manufacturing Stocks Facing Tariff Shifts

With fresh import tariffs returning under the Trump Administration and new trade probes targeting forced labor and industrial overcapacity, investors are being pushed to rethink how exposed their portfolios are to global supply chains. Larger U.S. manufacturers could stand to gain if domestic production becomes relatively more attractive; yet the picture is far from simple. This article breaks down how the renewed tariff push connects to U.S. Domestic Manufacturing Stocks and highlights three companies from that screener that appear to be notably affected by these trade shifts, helping you decide whether they deserve a closer look or a wider berth.

Overview: York Space Systems is a US based space and defense company that designs, builds and operates standardized satellite platforms and software for national security, government and commercial customers, covering the full mission lifecycle from spacecraft production to constellation operations.

Operations: York Space Systems generates about US$396.3 million in revenue entirely from Aerospace & Defense activities in the United States.

Market Cap: US$4.0b

York Space Systems sits at the intersection of US industrial policy and national security, with all its revenue tied to domestic Aerospace & Defense work at a time when new tariffs and supply chain scrutiny are pushing production onshore. The company is still loss making and relies on firm fixed price contracts, so cost overruns, integration risk from recent acquisitions and an inexperienced board could weigh on progress. Recent index inclusions, new US government contracts on its largest M CLASS platform and moves to secure US based solar and ground infrastructure also show how York is trying to build a tightly controlled, US centric supply chain that could matter even more as protectionist trade measures intensify.

York Space Systems appears to be an onshoring winner in the making, with fixed price contracts and acquisitions potentially masking the real story. Before you decide how to position around it, review the 3 key rewards and 1 important major warning sign.

NYSE:YSS Earnings & Revenue Growth as at Jun 2026

Overview: United States Antimony produces antimony based flame retardants, metals and chemicals, zeolite products, and recovers gold and silver, selling into end markets ranging from plastics and batteries to environmental cleanup and agriculture across the United States and Canada.

Operations: The company generates about US$35.8 million from Antimony and US$3.3 million from Zeolite, with roughly US$37.6 million of revenue in the United States and US$1.4 million in Canada.

Market Cap: US$1.2b

United States Antimony sits at the heart of the critical minerals conversation, as a US based producer that could directly benefit from new tariffs on foreign suppliers and potential US government support for secure antimony supply. The company is expanding smelting capacity at Thompson Falls to lift output. Analysts currently expect improvements in revenue and earnings, even though the business is loss making and carries funding and dilution risks. A rich valuation, short cash runway and leadership turnover mean execution and future demand need to justify the ambition. For investors watching how tariff policy and critical minerals policy develop, this is one of the more closely followed higher risk, higher potential names within US Domestic Manufacturing Stocks.

United States Antimony sits at the intersection of tariff pressure, critical minerals security and expansion plans, yet the full picture is not obvious. Get the fuller story from the 2 key rewards and 3 important warning signs (1 is major!)

NYSE:UAMY Earnings & Revenue Growth as at Jun 2026

Overview: Barloworld is an industrial processing and services company that supplies heavy equipment, power systems and industrial products to mining, construction and infrastructure customers, alongside a food and industrial ingredients business built around starch, glucose and related products. It operates across Southern Africa and select international markets, including the United Kingdom, Australia, Russia and Mongolia.

Operations: Barloworld generates about ZAR 31.0b from Equipment, ZAR 6.4b from Ingrain and ZAR 0.8b from Other activities, partly offset by ZAR 0.5b of eliminations.

Market Cap: US$1.1b

Barloworld provides exposure to heavy equipment and industrial processing at a time when US tariffs are encouraging more manufacturers to consider local production, and industrial goods suppliers may see stronger demand for onshore projects. The company has returned to profitability over the past five years, with earnings growing at about 25.2% per year and forecasts indicating further earnings growth. However, the high P/E ratio, premium to cash flow estimates and low 3.8% profit margin require investors to pay a higher price for that potential. In addition, the shares are highly illiquid, the company relies on external borrowing and it has a relatively new board, which highlights the risk side of the investment case. Recent stronger interim results, disciplined cost control and a focus on deleveraging and capital returns mean Barloworld is a stock many investors may want to understand more deeply before deciding where it could fit in a tariff-reshaped industrial supply chain.

Barloworld’s earnings recovery and high P/E suggest investors may be pricing in more than a simple industrial rebound. However, the real tension between profit margin, debt and future projects sits inside the 1 key reward and 1 important major warning sign

OTCPK:BRRA.Y Earnings & Revenue Growth as at Jun 2026

The three stocks covered here are only a sample of what tariffs and onshoring could mean for US Domestic Manufacturing Stocks, and the full US Domestic Manufacturing Stocks screener surfaces 42 more companies with equally compelling narratives around supply chains, pricing power and exposure to trade shifts. Use Simply Wall St to identify and analyze the specific catalysts, financial health markers and business narratives that matter most to you so you can focus on the ideas in this theme that align most closely with your own convictions.

Take Control of Your Investment Journey

If York Space Systems or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point.
Once you’ve made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates.
Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives.
By uncovering hidden catalysts and risks early, you’ll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Others?

New ideas often move first, and by the time the crowd notices, the most attractive entry points can be gone. Review these fresh stock groups while they are still relatively under the radar.

• Explore resilient momentum in companies with strong finances and lower risk profiles by reviewing the curated 66 resilient stocks with low risk scores before many investors are forced to react later.
• Identify income-oriented companies with payouts that may matter in a tariff-heavy environment by checking the hand picked 8 dividend fortresses while yields and prices still appear aligned.
• Follow companies tied to the evolution of the power grid by scanning the focused 34 power grid technology and infrastructure stocks while infrastructure spending themes are developing and attention has not fully shifted there yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Source link

AdvanCell Establishes U.S. Headquarters and Manufacturing Hub in Greater Boston

AdvanCell has established its U.S. Global Headquarters in the Greater Boston area and leased a 128,000-square-foot facility that will serve as its flagship U.S. manufacturing center, a move that expands the clinical-stage radiopharmaceutical company’s North American footprint and supports its long-term commercialization strategy.

The new facility, located at IQHQ’s Innovation Park campus in Andover, Massachusetts, will house both corporate operations and advanced manufacturing capabilities as AdvanCell continues to develop targeted alpha therapies for cancer. The investment marks a significant milestone in the company’s transition toward becoming a U.S.-based radiopharmaceutical organization with integrated operations spanning North America and Australia.

The expansion is designed to support the continued development of ADVC001, the company’s lead prostate cancer program, as well as its broader Lead-212 targeted alpha therapy pipeline. AdvanCell said the Andover site will become its first internal manufacturing facility in the United States, providing infrastructure to support future clinical and commercial production requirements.

“Establishing AdvanCell’s U.S. Global Headquarters and future manufacturing facility reinforces our commitment to U.S. expansion and represents an important milestone in AdvanCell’s strategy to build a global, vertically integrated targeted alpha therapy company,” said Chief Executive Officer Philina Lee, Ph.D.

Lee said the facility will play a central role in scaling production capabilities as the company advances ADVC001 and additional Lead-212 programs through clinical development. She noted that AdvanCell will continue to leverage its Australian operations for clinical translation, isotope supply and manufacturing process innovation while expanding its U.S. presence.

The Greater Boston region has become a major hub for biotechnology and radiopharmaceutical development, offering access to research institutions, manufacturing expertise, specialized talent and a deep life sciences ecosystem. By locating its headquarters and manufacturing operations in the area, AdvanCell gains proximity to key industry partners and resources needed to support future growth.

In addition to the Andover buildout, the company is working with a contract development and manufacturing organization to establish U.S.-based drug product manufacturing capabilities. AdvanCell said the dual-track strategy is expected to accelerate access to manufacturing capacity while the new facility is fitted out and qualified for production.

The approach is intended to support ongoing clinical development, including Phase 2 enrollment in the company’s TheraPb study in the United States, while creating the foundation for future Phase 3 and commercial-scale manufacturing operations.

AdvanCell’s lead candidate, 212Pb-ADVC001, is a prostate-specific membrane antigen (PSMA)-targeting radioligand designed for the treatment of prostate cancer. The therapy uses Lead-212, an alpha-emitting radionuclide with a 10.6-hour half-life, to deliver targeted radiation directly to cancer cells while limiting exposure to surrounding healthy tissue.

The ongoing TheraPb trial is a Phase 1/2 study evaluating ADVC001 in patients with metastatic prostate cancer. Following completion of the Phase 1b dose-escalation portion of the trial, the Phase 2 expansion stage is evaluating efficacy and safety across two dose levels. The study includes patients with PSMA-positive metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer.

Radiopharmaceutical development has emerged as one of the fastest-growing segments within oncology, driving increased investment in manufacturing infrastructure as companies seek to secure isotope supply chains and production capacity. Because radiopharmaceuticals have short shelf lives and complex production requirements, manufacturing scale and geographic reach are increasingly viewed as critical components of commercialization readiness.

For AdvanCell, the establishment of a U.S. headquarters and large-scale manufacturing facility represents a strategic investment in both operational infrastructure and future market access as it advances its targeted alpha therapy platform toward later-stage development and potential commercialization.

Source link

Trump says Intel will make chips for Apple in a major win for U.S. manufacturing

Intel’s efforts to rebuild its chipmaking business may have landed its biggest customer yet. U.S. President Donald Trump announced on Thursday that Apple has agreed to work with Intel to design and manufacture chips in the United States, a deal that could significantly strengthen Intel’s foundry ambitions.

The announcement does not come out of the blue. Earlier reports indicated that Apple and Intel had been discussing a manufacturing partnership for more than a year and had already begun working together on select chip production projects.

A major customer win for Intel

Trump announced the agreement in a post on Truth Social but did not specify which Apple chips Intel would manufacture. The president said the deal is part of his administration’s efforts to strengthen domestic chip production and support Intel’s recovery.

Landing Apple would be a major breakthrough for Intel Foundry. The company has spent years trying to attract major technology customers and prove it can compete with manufacturing leaders such as TSMC.

The Trump administration has also invested heavily in Intel’s future. Last year, the U.S. government took a 10% stake in the company and announced plans to invest roughly $10 billion to help build and expand semiconductor manufacturing facilities in the United States.

Intel and Apple have not officially announced the partnership, and neither company has publicly commented on Trump’s claims.

Intel

Intel’s foundry push is finally starting to show results

Recent developments suggest Intel’s manufacturing plans may finally be gaining momentum. The company recently announced that its 18A-P manufacturing process has entered risk production, a key milestone before large-scale manufacturing begins. Intel has also secured Tesla as a future customer for its 14A process, while reports suggest Nvidia could manufacture some products using Intel Foundry technology later this decade.

An Apple manufacturing deal would add significant weight to those efforts. Securing one of the world’s largest chip buyers would help validate Intel’s manufacturing roadmap and strengthen its position as it competes for more foundry customers. With TSMC facing strong demand for advanced manufacturing capacity and charging higher prices for access to its leading-edge processes, Intel has an opportunity to establish itself as a credible alternative for major chip designers.

Source link